Skip to main content
XFOR
NASDAQ Life Sciences

X4 Posts Narrower Q3 Loss, $187.7M Cash, and Details K2 Loan Covenants

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$3.24
Mkt Cap
$321.235M
52W Low
$2.43
52W High
$4.83
52W Position info
33% above low
Off High info
33% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

XFOR sits 33% above its 52-week low of $2.43.

Summary

X4 narrowed its Q3 2026 loss to $20.2M from $29.8M and ended September with $187.7M in cash and securities. The 10-Q also lays out the full terms of the October K2 refinancing, including a $15M conversion at $3.2341 and cash and revenue covenants that begin in 2027 and 2029.


Key Events · Earnings and Guidance · XFOR

  • Q3 Loss Narrows on Cost Cuts

    Net loss was $20.2M for Q3 2026 versus $29.8M a year earlier, with R&D down to $13.3M from $17.3M and G&A down to $9.1M from $11.6M after the 65% headcount reduction.

  • Product Revenue Nearly Doubles

    Net product revenue rose to $2.8M in Q3 2026 from $1.6M, and to $7.6M for the nine months from $4.3M, driven by more patients on XOLREMDI.

  • Cash Covers 12 Months, Burn $60.6M

    Cash, equivalents and short-term marketable securities totaled $187.7M at September 30, 2026 against $60.6M of nine-month operating cash use; management says funding lasts at least 12 months.

  • K2 Loan Terms and Covenants Detailed

    The $150M K2 facility funded an $80M first tranche on October 7, 2026 to repay Hercules; it carries 8.55% floor plus 1.55% over prime, 1.0% PIK, and a $15M conversion option at $3.2341 per share, maturing October 1, 2030.


Analysis · XFOR · Life Sciences

X4's third-quarter loss narrowed to $20.2M from $29.8M a year ago as restructuring cut R&D and G&A, and product revenue grew to $2.8M from $1.6M. The balance sheet carries $187.7M of cash and securities against a $56.6M nine-month operating burn, which management says funds operations and debt for at least 12 months. The bigger read-through is the K2 loan: the filing quantifies a $150M facility ($80M drawn October 7, 2026 to retire Hercules), a 1.0% PIK component, and a $15M conversion option at $3.2341 per share. The new covenants matter — starting October 1, 2027, if market cap is below $800M the company must hold unrestricted cash equal to 75% of outstanding obligations (dropping to 40% after conditions), and from April 1, 2029 it must hit 50% of board-projected net product revenue. Those are real constraints on a company whose product revenue is still under $10M a year.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, XFOR was trading at $3.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $321.2M. The 52-week trading range was $2.43 to $4.83. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XFOR - Latest Insights

XFOR
Nov 04, 2026, 4:15 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.24
Real-time Price: $2.80 info
Change: -$0.440 (-14%) info
Market Cap: $302.256M info
XFOR
Oct 29, 2026, 9:59 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.44
Real-time Price: $2.80 info
Change: -$0.640 (-19%) info
Market Cap: $302.256M info
XFOR
Oct 08, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.81
Real-time Price: $2.80 info
Change: -$0.0101 (-0.36%) info
Market Cap: $302.256M info
XFOR
Sep 08, 2026, 5:36 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.60
Real-time Price: $2.80 info
Change: -$0.800 (-22%) info
Market Cap: $302.256M info
XFOR
Sep 08, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.12
Real-time Price: $2.80 info
Change: -$1.32 (-32%) info
Market Cap: $302.256M info